Doses - CLORAZEPATE DIPOTASSIUM

Dogs:

As an adjunctive medication in the treatment of seizures:
a) 2 mg/kg PO q12h (Papich 1992)
b) 1 -2 mg/kg PO q12h (Fenner 1994)
c) 0.5 mg/kg PO bid-tid; may need to lower phenobarbital dose by 10-20%. (Neer 1994)
As adjunctive therapy for the treatment of fears and phobias:
a) 11.25 - 22.5 mg per dog PO once to twice daily (recommends the sustained delivery - "Tranxene®-SD") product. (Marder 1991)
b) Using the sustained delivery product ("Tranxene®-SD"), initially give 22.5 mg for large dogs, 11.25 mg for medium dogs and 5.6 mg for small dogs PO; adjust dosage according dog's response. (Shull-Selcer and Stagg 1991)
Monitoring Parameters -1) Efficacy; 2) Adverse Effects
Client Information - A major factor in anticonvulsant therapy failure is lack of compliance withthe prescribed therapy. Owners must be counseled on the importance of giving doses regularly.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None

Human-Approved Products:

Note: All clorazepate products are controlled drugs (C-IV).
Clorazepate dipotassium capsules 3.75 mg, 7.5 mg, 15 mg; generic; (Rx)
Clorazepate dipotassium tablets sustained-release (single dose) 11.25 mg, 22.5 mg; Tranxene-SD® (Abbott); (Rx);Tranxene-SD Half Strength® (Abbott) (Rx)
Clorazepate dipotassium tablets 3.75 mg, 7.5 mg, 11.25 mg, 15 mg, 22.5 mg; Tranxene®(Abbott), Gen-Xene®(Alra), generic; (Rx)